SPRAVATO® is a prescription nasal spray approved by the FDA to treat adults diagnosed with:
Treatment-Resistant Depression (TRD): For individuals who have not achieved sufficient symptom relief despite trying at least two other antidepressant therapies.
Major Depressive Disorder (MDD) with Acute Suicidal Ideation or Behavior: A prompt-acting treatment option for those experiencing intense depressive episodes with immediate safety concerns.
Unlike many antidepressants that require several weeks to show results, SPRAVATO® has demonstrated noticeable symptom improvement in as little as 24 hours in clinical studies.
SPRAVATO® offers a distinct method for managing depressive symptoms. Administered under the care of licensed medical staff, this nasal spray activates NMDA receptors in the brain, helping to deliver rapid and effective relief.
All treatments are provided in certified clinical facilities. Each session includes a post-dose observation period of at least two hours to monitor your response and ensure safety.
Begin with a no-obligation phone consultation. If initial criteria are met, our mental health professionals will conduct a full clinical review, including your treatment background. If eligible, we assist in confirming your insurance benefits with participating providers.
Once coverage is verified, your treatment begins. Each SPRAVATO® session is administered under strict medical oversight. Patients self-administer the nasal spray while being monitored in a controlled, supportive environment for at least two hours.
Your treatment typically begins with twice-weekly sessions in the induction phase. This gradually transitions into a personalized maintenance schedule, based on your progress and long-term goals.
We continue to support your recovery through regular follow-ups. Adjustments to your treatment plan will be made as needed. We also maintain communication with your other healthcare providers to ensure cohesive, coordinated care.
Week 1-4
2 Treatments a Week
Week 5-8
1 Treatments a Week
Week 9+
Treatment frequency will be determined based on patients needs.
Response Rate: Traditional antidepressants typically show a response rate of 40-60%, while SPRAVATO® (esketamine) has demonstrated response rates of up to 70% in clinical trials (Popova et al., 2019, American Journal of Psychiatry).
Time to Noticeable Effect: Traditional antidepressants often take 4-6 weeks for noticeable improvements, whereas patients using SPRAVATO® (esketamine) may experience relief within 24 hours, as observed in clinical trials (BMC Psychiatry, 2022).
Sustained Remission Rate: Traditional antidepressants achieve sustained remission rates of approximately 15-30%, but SPRAVATO® has shown remission rates as high as 80% when combined with an oral antidepressant (Wilkinson et al., 2018, Nature Reviews Drug Discovery).
We follow FDA guidance and use only approved therapies. While some clinics may use off-label ketamine, we focus exclusively on treatments backed by clinical research.
Healing is influenced by surroundings. Our clinic is designed with calming, thoughtful aesthetics to support your well-being throughout treatment.
If you’re already working with a therapist or psychiatrist, we ensure full coordination so all aspects of your care work in harmony.
We work with your insurance and handle all necessary paperwork.
Over 3,000+ Boise residents have used SPRAVATO® to elevate their lives.
Avoid driving until the following day after a good night’s rest.
Download our comprehensive PDF guides to learn about SPRAVATO®, its benefits, uses, and other important safety information.
